Thursday, February 16, 2023
A revolutionary test that can measure the progression and durability of Chimeric Antigen Receptor T-Cell (CAR-T) treatment in patients with pre-B cell acute lymphoblastic leukaemia and B cell lymphomas has been made available, according to Eurofins Viracor LLC.
The test is made to make it easier for clinicians to comprehend how CAR-T therapy is working for their patients.
CAR-T therapy is a cutting-edge type of immunotherapy that uses genetically modified T-cells to target cancer cells and has demonstrated promising outcomes in the treatment of a number of cancers.
The test is intended to give clinicians a precise and thorough evaluation of the CAR-T cell population in the patient's body and may provide information about the efficacy of the therapy.
The launch of this test represents a significant advancement in the assessment and administration of CAR-T treatment for cancer patients.
It is anticipated to be a useful tool for assisting clinicians in selecting the most appropriate course of therapy for their patients.
